Non-alcoholic Fatty Liver Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In more advanced stages, FSTL3 levels are higher in NASH compared to SS and, within NAFLD patients, in those with more severe lobular and portal inflammation.
|
31690932 |
2020 |
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
It was previously reported that follistatin-like 3(FSTL3), an activin A binding protein, contributes to the invasion and migration of trophoblast.
|
31810141 |
2020 |
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression.
|
31815869 |
2019 |
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression.
|
31815869 |
2019 |
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
We assessed the predictive value of GAL3 (galectin-3), FSTL3 (follistatin-like 3 peptide), and NT-proBNP (N-terminal pro-B-type natriuretic peptide) to identify stage B MHD in young obese participants free of clinically evident cardiovascular disease.
|
30929550 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We investigated this hypothesis in humans by studying the physiology of a possible glycaemia-follistatin feedback loop, that is, whether glucose, but not lipid intake (oral or intravenous), can regulate circulating FST and FSTL3 in healthy humans (n = 32), whether the levels of follistatins change in response to various types of bariatric operation in morbidly obese individuals, with or without type 2 diabetes (n = 41), and whether such changes are associated prospectively with improvement of glucose homeostasis/insulin sensitivity.
|
30393997 |
2019 |
Cerebrovascular accident
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Framingham 10-year stroke risk (FSRP-10) quantified CVD-RFs.
|
30980900 |
2019 |
Takayasu Arteritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Considering this, we further built a logistic regression model based on multiple cytokines, including CA (cancer antigen) 125, FLRG (follistatin-related protein), IGFBP (insulin-like growth factor-binding protein)-2, CA15-3, GROa (growth-regulated alpha protein), LYVE (lymphatic vessel endothelial hyaluronic acid receptor)-1, ULBP (UL16-binding protein)-2, and CD (cluster of differentiation) 99, with an area under the curve reaching 0.909 for discriminating TA activity status.
|
30645172 |
2019 |
Dyslipidemias
|
0.010 |
Biomarker
|
group |
BEFREE |
FSTL3 as adipokine takes part in dyslipidemia and inflammatory response, but the association of FSTL3 with atherosclerosis is unclear.
|
31815869 |
2019 |
Asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To quantify the abundance of the total proteome FSTL3 and activin A in supernatants of differentiated BEC cultures from healthy children and children with asthma, we performed mass spectrometry and ELISA.
|
29394092 |
2018 |
Metabolic Syndrome X
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Activin A, activin B, follistatin, and FSTL3 were measured in (1) 80 subjects divided according to age (young vs old) and fitness status (active vs sedentary) before and after exercise at 70% maximal oxygen consumption (VO2max), followed by 90% of VO2max until exhaustion; and (2) 23 subjects [9 healthy and 14 with metabolic syndrome (MetS)] who completed four sessions: no exercise, high-intensity interval exercise, continuous moderate-intensity exercise, and resistance exercise for up to 45 minutes.
|
30085147 |
2018 |
Limb ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
When iPS-ECs overexpressing FSTL3 were subcutaneously injected in in vivo angiogenic model or intramuscularly injected in a hind limb ischemia NOD.CB17-Prkdcscid/NcrCrl SCID mice model, FSTL3 significantly induced angiogenesis and blood flow recovery, respectively.
|
29569797 |
2018 |
Gestational Diabetes
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
There were no significant differences in serum FSTL3 levels (p = 0.578) between the GDM group and the GDM-free control group.
|
27623975 |
2017 |
Invasive carcinoma of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
FSTL3 expression in invasive breast cancer is inversely associated with tumor size and nuclear grade but it does not predict disease relapse in the short term.
|
28178680 |
2017 |
Chronic Kidney Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Moreover, mFSTL3 mRNA expression was investigated in an animal CKD model, that is, eNOS-/-db/db mice, and compared with littermate controls.
|
28339962 |
2017 |
Renal Insufficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
In both human CKD and AKD, renal dysfunction remained the strongest independent predictor of FSTL3 serum concentrations in multivariate analyses.
|
28339962 |
2017 |
Fatty Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Both FSTL3-knockout and FST288-only mice had extensive hepatic steatosis and elevated hepatic triglyceride content.
|
23533219 |
2013 |
Cardiac fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found that FSTL3 is necessary for this response and for the induction of cardiac fibrosis.
|
22915069 |
2012 |
Diminished ovarian reserve
|
0.010 |
Biomarker
|
disease |
BEFREE |
Forty-eight transcripts were differentially expressed, including CXXC finger protein 5 (CXXC5), forkhead box C1 (FOXC1) (down-regulated in DOR) as well as connective tissue growth factor (CTGF), follistatin-like 3 (FSTL3), prostaglandin-endoperoxide synthase 2 (PTGS2) and suppressor of cytokine signaling 2 (SOCS2) (up-regulated in DOR).
|
22246450 |
2012 |
Eclampsia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overproduction of the follistatin-related gene protein in the placenta and maternal serum of women with pre-eclampsia.
|
17617189 |
2007 |
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth.
|
17671190 |
2007 |
Liver neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Expression levels of follistatin, follistatin-like 3, and activin subunits beta(A) as well as beta(E) were investigated in chemically induced rat and human liver tumours by real-time PCR and immunohistochemistry.
|
16935389 |
2006 |
Rheumatoid Arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Follistatin-related protein gene (FRP) is expressed in the synovial tissues of rheumatoid arthritis, but its polymorphisms are not associated with genetic susceptibility.
|
15638044 |
2005 |
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The expression of NEDD8, calponin, and the follistatin-related protein in normal prostate tissues is a novel finding and the role of these important functional proteins in normal prostate and their loss or reduced expression in prostate malignancy warrants further investigations.
|
11757036 |
2002 |
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The expression of NEDD8, calponin, and the follistatin-related protein in normal prostate tissues is a novel finding and the role of these important functional proteins in normal prostate and their loss or reduced expression in prostate malignancy warrants further investigations.
|
11757036 |
2002 |